| ALCON |
ALCON |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| NVS |
Novartis AG |
92%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from YDES graph: Reciprocal relationship from NVS graph: Reciprocal relationship from YDES graph: Reciprocal relationship from NVS grap… |
| NVS |
Novartis AG |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| ZUELLING |
ZUELLING |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| BNR |
Burning Rock Biotech Limited |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| BNR |
Burning Rock Biotech Limited |
72%
|
Reciprocal relationship from BNR graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top… |
| CAPR |
Capricor Therapeutics, Inc. |
72%
|
Reciprocal relationship from CAPR graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s to… |
| CAPR |
Capricor Therapeutics, Inc. |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| EXAS |
Exact Sciences Corp |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| EXAS |
Exact Sciences Corp |
72%
|
Reciprocal relationship from EXAS graph: Reciprocal relationship from YDES graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from YDES graph: Reciprocal relationship from EXAS g… |
| GH |
Guardant Health, Inc. |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top … |
| JNJ |
Johnson & Johnson |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from YDES graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the… |
| EG-BIOMED-LIMITED |
EG-BIOMED-LIMITED |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
| EG-BIOMED-US-INC |
EG-BIOMED-US-INC |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
| GLOBAL-BIOTECH-INC |
GLOBAL-BIOTECH-INC |
62%
|
025 14,400 223,425 Beauty products 49,841 70 49,911 Contact lenses 35,000 — 35,000 Nutritional products 5,000 234 5,234 Supplements 2,405 68 2,473 Total $ 581,990 $ 14,827 $ 596,817 The Company opera… |
| IMARC-GROUP |
IMARC-GROUP |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
| IVD-REGULATORY-ADVISORS-LLC |
IVD-REGULATORY-ADVISORS-LLC |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
s. Decreasing demand from our customers or increased prices quoted by our suppliers may materially and adversely affect our future results of operations. Risks Related to Intellectual Property Rights… |
| ORGANIZATION-YD-BIO-LIMITED |
ORGANIZATION-YD-BIO-LIMITED |
62%
|
147 ) Adjustment to deferred offering costs ( 3,848,212 ) ( 3,848,212 ) Net loss — — — ( 8,311,316 ) — ( 8,311,316 ) Foreign currency translation adjustment — — — — 168,864 168,864 Balance at Decembe… |
| SHEN-CAPITAL-CO-LTD |
SHEN-CAPITAL-CO-LTD |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
| TECHNOLOGY-CO-LTD |
TECHNOLOGY-CO-LTD |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
| U-S-BASED-CRO-ARBELOS-GENOMICS-INC |
U-S-BASED-CRO-ARBELOS-GENOMICS-INC |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
| YC-BIOTECH-CO-LTD |
YC-BIOTECH-CO-LTD |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
| YD-BIO-LIMITED |
YD-BIO-LIMITED |
62%
|
147 ) Adjustment to deferred offering costs ( 3,848,212 ) ( 3,848,212 ) Net loss — — — ( 8,311,316 ) — ( 8,311,316 ) Foreign currency translation adjustment — — — — 168,864 168,864 Balance at Decembe… |
| YD-BIO-LIMITED-COMPANY |
YD-BIO-LIMITED-COMPANY |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
| YD-BIO-USA-INC |
YD-BIO-USA-INC |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
| YONG-DING-BIOPHARM-CO-LTD |
YONG-DING-BIOPHARM-CO-LTD |
62%
|
ted terms or at all. On January 20, 2026, the Company entered into a binding Letter of Intent (LoI) to acquire 100% of the equity interests in Safe Save Medical Cell Sciences & Technology Co., Ltd. (… |
